Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma
OS and PFS were longer with ENCO + BINI relative to DAB + TRAM and comparable to VEM + COBI, after adjusting for differences in patient profiles. These findings add to evidence informing the use of combination v-Raf murine sarcoma viral oncogene homolog B protein (BRAF)/mitogen-activated protein kinase kinase (MEK) inhibitors in metastatic BRAF V600-mutant melanoma.
Authors
- Gino K. In (ORCID: https://orcid.org/0000-0002-7060-5123)
- K. Chen
- Daniel Liu (ORCID: https://orcid.org/0000-0002-4153-504X)
- Dennis Christensen (ORCID: https://orcid.org/0000-0003-2382-8639)
- James Signorovitch (ORCID: https://orcid.org/0000-0002-4067-8962)
- Ryan Simpson (ORCID: https://orcid.org/0000-0002-1375-5387)
- Gautam Sajeev (ORCID: https://orcid.org/0000-0002-1827-8938)
- Sunil Kalia (ORCID: https://orcid.org/0000-0002-5271-5273)
- Alessandra di Pietro
- N. Rezai
Institutions
- Pfizer (United States) (US)
- USC Norris Comprehensive Cancer Center (US)
- Pfizer (Italy) (IT)
- Analysis Group (United States) (US)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1016/j.esmorw.2024.100071
- Citations
- 2
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Pfizer